ProCE Banner Activity

CME

Optimizing Frontline Therapy in Ovarian Cancer Using PARP Inhibitors: A Video Roundtable

Watch this video roundtable with 3 experts discussing the latest clinical data informing the optimal management of patients with ovarian cancer using PARP inhibitors as frontline maintenance.

This educational program is intended for healthcare professionals practicing medicine outside of the United States.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: May 21, 2021

Expiration: May 20, 2022

No longer available for credit.

Share

Faculty

Nicoletta Colombo

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Thomas J. Herzog

Thomas J. Herzog, MD

Associate Professor
Division of Gynecology
Washington University
St Louis, Missouri

Ignace Vergote

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by an educational grant from

GlaxoSmithKline

Target Audience

This educational program is intended for ex-US gynecologic oncologists, medical oncologists, nurses, and other healthcare professionals who treat patients with ovarian cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Appraise the available data supporting the use of PARP inhibitors as frontline maintenance therapy for patients with and without BRCA-associated cancers 
  • Plan frontline maintenance therapy for patients with or without BRCA mutations or other defects in homologous recombination repair 
  • Evaluate the differences among PARP inhibitors regarding evolving global indications, dosing, administration, efficacy, and treatment-related adverse events

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Nicoletta Colombo, MD, has disclosed that she has received consulting fees from AstraZeneca, Biocad, Clovis, Eisai, GSK, Immunogen, Mersana, MSD/Merck, Pfizer, PharmaMar, Roche, Takeda, and Tesaro; Fees for Non-CME/CE Services from AstraZeneca, Novartis and Tesaro; and fees for research support from AstraZeneca, PharmaMar, and Roche.

Thomas J. Herzog, MD

Associate Professor
Division of Gynecology
Washington University
St Louis, Missouri

Thomas J. Herzog, MD, has disclosed that he has received consulting fees from Aravive, AstraZeneca, Caris, Clovis, Eisai, Genentech, GlaxoSmithKline, Merck, and Seagen.

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Ignace Vergote, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Elevar, Genmab, GlaxoSmithKline, Immunogen, MSD, Oncoinvent, and Roche; and funds for research support from Genmab and Roche.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 21, 2021, through May 20, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge and competence of global learners to optimally integrate current data needed to make treatment decisions and improve clinical outcomes in patients with ovarian cancer.